What’s the current market cap for ArriVent BioPharma stock?

ArriVent BioPharma (AVBP) has a market cap of $1.2B as of May 25, 2026.

What is the P/E ratio for ArriVent BioPharma stock?

The price to earnings (P/E) ratio for ArriVent BioPharma (AVBP) stock is 0 as of May 25, 2026.

Does ArriVent BioPharma stock pay dividends?

No, ArriVent BioPharma (AVBP) stock does not pay dividends to its shareholders as of May 25, 2026.

When is the next ArriVent BioPharma dividend payment date?

ArriVent BioPharma (AVBP) stock does not pay dividends to its shareholders.

What is the beta indicator for ArriVent BioPharma?

ArriVent BioPharma (AVBP) has a beta rating of 1.52. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.

Buy ArriVent BioPharma stock | $AVBP Share Price

13:30

15:10

16:45

18:25

20:00

About ArriVent BioPharma

ArriVent BioPharma Inc is a clinical-stage biopharmaceutical company dedicated to the identification, development, and commercialization of differentiated medicines to address the unmet medical needs of patients with cancers. The company focuses on advancing its lead product candidate, firmonertinib, for the treatment of epidermal growth factor receptor (EGFR) mutant non-small cell lung cancer (NSCLC), and developing a pipeline of novel therapeutics, including next-generation antibody-drug conjugates such as ARR-217 (MRG007), with an initial focus on solid tumors.

Ticker

$AVBP

Sector

Health

Primary listing

NASDAQ

Employees

Headquarters

Newtown Square, United States

Website

arrivent.com

AVBP Metrics

BasicAdvanced

$1.2bn

-$3.52

1.52

What the Analysts think about AVBP

Analyst ratings (Buy, Hold, Sell) for ArriVent BioPharma stock.

Bulls say / Bears say

Enrollment is ongoing in the global Phase 3 ALPACCA trial of firmonertinib as a first-line treatment for EGFR PACC mutant NSCLC, moving the company closer to a potential new indication (Nasdaq).

Enrollment was completed in the global FURVENT Phase 3 study of firmonertinib for first-line EGFR exon 20 insertion mutant NSCLC. Topline data is expected in mid-2026, supporting possible registration of the candidate (Nasdaq).

The ARR-217 (MRG007) antibody-drug conjugate program moved into Phase 1 clinical trials, with the first patient dosed in March 2026, expanding the pipeline into gastrointestinal cancers (Nasdaq).

Net loss increased to $166.3 million in 2025, more than double the $80.5 million loss in 2024, indicating a steep cash burn rate amid ongoing trials (Nasdaq).

Data summarised monthly by Lightyear AI. Last updated on 24 May 2026.

AVBP Financial Performance

Revenues and expenses

QuarterlyAnnual

Q3 24

QoQ growth

Revenue

$37bn

-39.75%

Net income

$45bn

107.52%

Profit margin

37.65%

6.78%

AVBP Earnings Performance

Company profitability

QuarterlyAnnual

Q4 23

Q1 24

Q2 24

Q3 24

Q4 24

Actual

$3.69

$2.85

$2.45

$2.42

Expected

$3.55

$2.61

$2.05

$2.31

$3.94

Surprise

3.94%

9.20%

19.51%

4.63%

Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.

Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.

Buy $AVBP

Capital at risk

Market closed

Upcoming events

No upcoming events

Bulls say / Bears say

Enrollment is ongoing in the global Phase 3 ALPACCA trial of firmonertinib as a first-line treatment for EGFR PACC mutant NSCLC, moving the company closer to a potential new indication (Nasdaq).

The ARR-217 (MRG007) antibody-drug conjugate program moved into Phase 1 clinical trials, with the first patient dosed in March 2026, expanding the pipeline into gastrointestinal cancers (Nasdaq).

Net loss increased to $166.3 million in 2025, more than double the $80.5 million loss in 2024, indicating a steep cash burn rate amid ongoing trials (Nasdaq).

Data summarised monthly by Lightyear AI. Last updated on 24 May 2026.

About ArriVent BioPharma

Ticker

Employees

AVBP Metrics

Price and volume

Financial strength

Profitability

Management effectiveness

Valuation

Growth

What the Analysts think about AVBP

Analyst Ratings

Bulls say / Bears say

AVBP Financial Performance

Income Statement

AVBP Earnings Performance

Earnings per share (EPS)

Buy $AVBP

Upcoming events

No upcoming events

Lightyear

Legal

Work with us

Bulls say / Bears say

ArriVent BioPharma/$AVBP

About ArriVent BioPharma

Ticker

Employees

AVBP Metrics

Price and volume

Financial strength

Profitability

Management effectiveness

Valuation

Growth

What the Analysts think about AVBP

Analyst Ratings

Bulls say / Bears say

AVBP Financial Performance

Income Statement

AVBP Earnings Performance

Earnings per share (EPS)

Buy $AVBP

Upcoming events

No upcoming events

What’s the current market cap for ArriVent BioPharma stock?

What is the P/E ratio for ArriVent BioPharma stock?

Does ArriVent BioPharma stock pay dividends?

When is the next ArriVent BioPharma dividend payment date?

What is the beta indicator for ArriVent BioPharma?

Bulls say / Bears say